SCHEMBL1702825

SCHEMBL1702825

Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)ccnc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.78
KIT P10721 13/20 0.78
BLK P51451 12/20 0.78
CSF1R P07333 12/20 0.78
FLT3 P36888 12/20 0.78
FLT1 P17948 12/20 0.78
LCK P06239 11/20 0.78
LYN P07948 11/20 0.78
FLT4 P35916 10/20 0.78
ABL1 P00519 7/20 0.78
SRC P12931 7/20 0.78
FYN P06241 7/20 0.78
AURKB Q96GD4 7/20 0.59
AURKA O14965 7/20 0.59
ROCK2 O75116 7/20 0.59
MAP4K4 O95819 7/20 0.59
FGFR1 P11362 7/20 0.59
NEK2 P51955 7/20 0.59
ROCK1 Q13464 7/20 0.59
TAOK1 Q7L7X3 7/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703567 0.89 KIT (0.83) KDRKITBLKCSF1RFLT3
SCHEMBL2821081 0.89 KIT (0.78) KDRKITBLKCSF1RFLT3
SCHEMBL1703181 0.88 KDR (0.75) KDRKITBLKCSF1RFLT3
SCHEMBL1703605 0.88 KDR (1.00) KDRKITBLKCSF1RFLT3
SCHEMBL1703245 0.86 KDR (0.78) KDRKITBLKCSF1RFLT3
SCHEMBL13135808 0.86 KDR (0.61) KDRKITBLKCSF1RFLT3
SCHEMBL425683 0.85 KDR (0.79) KDRKITBLKCSF1RFLT3
SCHEMBL1703118 0.84 KIT (0.74) KDRKITBLKCSF1RFLT3
SCHEMBL1702853 0.84 KDR (1.00) KDRKITBLKCSF1RFLT3
SCHEMBL1703132 0.84 CSF1R (1.00) KDRKITBLKCSF1RFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885BLK 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.